Kezar Life Sciences, INC Schedule 13G passive stakes

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Kezar Life Sciences, Inc.

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Kezar Life Sciences, Inc.

BML Investment Partners, L.P. has filed a Schedule 13G amendment indicating no beneficial ownership of Kezar Life Sciences, Inc. common stock as of May 11, 2026.

Baselake Partners, LP, along with its management entity and managing member, has reported a 5.3% beneficial ownership stake in Kezar Life Sciences, Inc.

Stonepine Capital Management and related entities have reported a 2.1% passive beneficial ownership stake in Kezar Life Sciences, Inc. as of December 31, 2025.

BML Investment Partners, L.P. has reported a 9.8% beneficial ownership stake in Kezar Life Sciences, Inc., holding 720,787 shares of common stock.

Avidity Partners and related entities have fully divested their beneficial ownership in Kezar Life Sciences, Inc., reporting 0.0% ownership.

Stonepine Capital Management and its affiliates have reported a passive 5.2% beneficial ownership stake in Kezar Life Sciences, Inc.

Barclays PLC has filed an amended Schedule 13G, indicating a passive ownership stake of 5% or less in Kezar Life Sciences Inc. as of September 30, 2024.

BML Investment Partners, L.P. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.1% in Kezar Life Sciences, Inc.'s common stock.

Avidity Partners and its affiliated entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 6.9% of Kezar Life Sciences, Inc.'s common stock as of December 31, 2024.